Low rate of complications in nipple-sparing mastectomy for patients with and mutation.

To describe the indications and outcomes of mutation carriers undergoing nipple-sparing mastectomy (NSM). In this retrospective study, 76 mutation carriers with no cancer who opted to undergo risk reduction NSM or diagnosed with breast cancer (BC) who opted to undergo therapeutic NSM were included. Indications for NSM: cancer treatment (n = 33), bilateral risk reduction (n = 39) and contralateral prophylactic NSM (n = 4). In a mean follow-up of 45 months (median: 30 months), one patient (2.5%) undergoing risk-reducing NSM developed a new BC. One (3%) local, one (3%) ipsilateral axillary and one (3%) distant recurrence were observed in BC patients. No partial or total nipple necrosis occurred. NSM is safe for reducing the risk of BC development in mutation carriers and for treating cancer.